Targeting the nicotinic acetylcholine receptors (nAChRs) in astrocytes as a potential therapeutic target in Parkinson’s disease

Current Pharmaceutical Design

Volumn 22, Issue 10, 2016, Pages 1305-1311

  Jurado Coronel, Juan Camilo ^a   Ávila Rodriguez, Marco ^a   Capani, Francisco ^b,c   Gonzalez, Janneth ^a   Morán, Valentina Echeverría ^d,e   Barreto, George E ^a,f  

^a PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^b Instituto de Investigaciones Cardiologicos Dr Alberto C Taquini   (Argentina)

^c UAJFK   (Argentina)

^d UNIVERSIDAD SAN SEBASTIÁN   (Chile)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

Author keywords

Apoptosis; Astrocytes; nAChRs; Neuroinflammation; Neuroprotection; Nicotine; Parkinson disease

Indexed keywords

NICOTINE; NICOTINIC RECEPTOR; NEUROPROTECTIVE AGENT;

APOPTOSIS; ARTICLE; ASTROCYTE; CELL ACTIVATION; COGNITIVE DEFECT; DISABILITY; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; GAIT DISORDER; GLIA CELL; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MUSCLE RIGIDITY; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; QUALITY OF LIFE; SUBSTANTIA NIGRA PARS COMPACTA; TREMOR; ANIMAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ANIMALS; ASTROCYTES; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RECEPTORS, NICOTINIC;

EID: 84961710113     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161282210160304112133     Document Type: Article

References (87)

1. Cabezas R, Avila M, Gonzalez J, et al. Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease. Front Cell Neurosci 2014; 8: 211
2. Dos Santos AB, Barreto GE, Kohlmeier KA. Treatment of sleeping disorders should be considered in clinical management of Parkinson's disease. Front Aging Neurosci 2014; 6: 273
3. dos Santos AB, Kohlmeier KA, Barreto GE. Are sleep disturbances preclinical markers of Parkinson's disease? Neurochem Res 2015; 40: 421-7
4. Wang X, Lippi G, Carlson DM, Berg DK. Activation of alpha7- containing nicotinic receptors on astrocytes triggers AMPA receptor recruitment to glutamatergic synapses. J Neurochem 2013; 127: 632-43
5. Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS. Environmental risk factors and Parkinson's disease: a metaanalysis. Environ Res 2001; 86: 122-7
6. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009; 8: 382-97
7. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005; 28: 57-87
8. Son IH, Park YH, Yang HD, et al. Nicotine suppresses TNF-α expression in human fetal astrocyte through the modulation of nuclear factor-κB activation. Mol Cell Toxicol 2008; 4: 106-12
9. Tufekci KU, Genc S, Genc K. The endotoxin-induced neuroinflammation model of Parkinson's disease. Parkinsons Dis 2011; 2011: 487450
10. Park HJ, Lee PH, Ahn YW, et al. Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action. Eur J Neurosci 2007; 26: 79-89
11. Barreto G, White RE, Ouyang Y, Xu L, Giffard RG. Astrocytes: targets for neuroprotection in stroke. Cent Nerv Syst Agents Med Chem 2011; 11: 164-73
12. Barreto GE, Gonzalez J, Torres Y, Morales L. Astrocytic-neuronal crosstalk: implications for neuroprotection from brain injury. Neurosci Res 2011; 71: 107-13
13. Wang DD, Bordey A. The astrocyte odyssey. Prog Neurobiol 2008; 86: 342-67
14. Cabezas R, Avila MF, Gonzalez J, El-Bacha RS, Barreto GE. PDGF-BB Protects mitochondria from rotenone in T98G cells. Neurotox Res 2015; 27: 355-67
15. Cabezas R, El-Bacha RS, Gonzalez J, Barreto GE. Mitochondrial functions in astrocytes: neuroprotective implications from oxidative damage by rotenone. Neurosci Res 2012; 74: 80-90
16. Ridet JL, Malhotra SK, Privat A, Gage FH. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci 1997; 20: 570-7
17. Carnevale D, De Simone R, Minghetti L. Microglia-neuron interaction in inflammatory and degenerative diseases: role of cholinergic and noradrenergic systems. CNS Neurol Disord Drug Targets 2007; 6: 388-97
18. Chung YC, Ko HW, Bok E, et al. The role of neuroinflammation on the pathogenesis of Parkinson's disease. BMB Rep 2010; 43: 225-32
19. Hernandez-Morales M, Garcia-Colunga J. Effects of nicotine on K+ currents and nicotinic receptors in astrocytes of the hippocampal CA1 region. Neuropharmacology 2009; 56: 975-83
20. Hu ZJ, Bai L, Tizabi Y, Southerland W. Computational modeling study of human nicotinic acetylcholine receptor for developing new drugs in the treatment of alcoholism. Interdiscip Sci 2009; 1: 254-62
21. Wang J, Li X, Yuan Q, Ren J, Huang J, Zeng B. Synthesis and pharmacological properties of 5-Alkyl substituted nicotine analogs. Chinese J Chem 2012; 30: 2813-8
22. Yuan H, Petukhov PA. Computational evidence for the ligand selectivity to the alpha4beta2 and alpha3beta4 nicotinic acetylcholine receptors. Bioorg Med Chem 2006; 14: 7936-42
23. Chen H, Huang X, Guo X, et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology 2010; 74: 878-84
24. Fratiglioni L, Wang HX. Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies. Behav Brain Res 2000; 113: 117-20
25. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009; 373: 2055-66
26. Ritz B, Ascherio A, Checkoway H, et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 2007; 64: 990-7
27. Bencherif M, Lippiello PM, Lucas R, Marrero MB. Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases. Cell Mol Life Sci 2011; 68: 931-49
28. Conejero-Goldberg C, Davies P, Ulloa L. Alpha7 nicotinic acetylcholine receptor: a link between inflammation and neurodegeneration. Neurosci Biobehav Rev 2008; 32: 693-706
29. Gotti C, Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 2004; 74: 363-96
30. Quik M, Huang LZ, Parameswaran N, Bordia T, Campos C, Perez XA. Multiple roles for nicotine in Parkinson's disease. Biochem Pharmacol 2009; 78: 677-85
31. Liu Y, Zeng X, Hui Y, et al. Activation of alpha7 nicotinic acetylcholine receptors protects astrocytes against oxidative stressinduced apoptosis: implications for Parkinson's disease. Neuropharmacology 2015; 91: 87-96
32. Graham AJ, Ray MA, Perry EK, et al. Differential nicotinic acetylcholine receptor subunit expression in the human hippocampus. J Chem Neuroanat 2003; 25: 97-113
33. Dutta G, Zhang P, Liu B. The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol 2008; 22: 453-64
34. Le W, Rowe D, Xie W, Ortiz I, He Y, Appel SH. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J Neurosci 2001; 21: 8447-55
35. Li Z, Cao J, Ren X, Zhao Q, Zhou M, Zang W. Nicotine protects dopaminergic neurons against lipopolysaccharide-induced damage through _7 nAChRs in microglia. Life Sci J 2013; 10: 1198-203
36. Mogi M, Harada M, Kondo T, Riederer P, Nagatsu T. Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Short communication. J Neural Transm 1996; 103: 1077-81
37. McNaught KS, Jenner P. Dysfunction of rat forebrain astrocytes in culture alters cytokine and neurotrophic factor release. Neurosci Lett 2000; 285: 61-5
38. Liu Y, Hu J, Wu J, et al. alpha7 nicotinic acetylcholine receptormediated neuroprotection against dopaminergic neuron loss in an MPTP mouse model via inhibition of astrocyte activation. J Neuroinflamm 2012; 9: 98
39. Ling ZD, Chang Q, Lipton JW, et al. Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain. Neuroscience 2004; 124: 619-28
40. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Ann Rev Immunol 1998; 16: 225-60
41. Hong DP, Fink AL, Uversky VN. Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation? Biochim Biophys Acta 2009; 1794: 282-90
42. Quik M, Perez XA, Bordia T. Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov Disord 2012; 27: 947-57
43. Shimohama S. Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models. Biol Pharm Bull 2009; 32: 332-6
44. Ward RJ, Lallemand F, de Witte P, Dexter DT. Neurochemical pathways involved in the protective effects of nicotine and ethanol in preventing the development of Parkinson's disease: potential targets for the development of new therapeutic agents. Prog Neurobiol 2008; 85: 135-47
45. Bradford ST, Stamatovic SM, Dondeti RS, Keep RF, Andjelkovic AV. Nicotine aggravates the brain postischemic inflammatory response. Am J Physiol Heart Circ Physiol 2011; 300: H1518-29
46. Zhou FM, Liang Y, Dani JA. Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat Neurosci 2001; 4: 1224-9
47. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001; 292: 727-30
48. Oikawa H, Nakamichi N, Kambe Y, Ogura M, Yoneda Y. An increase in intracellular free calcium ions by nicotinic acetylcholine receptors in a single cultured rat cortical astrocyte. J Neurosci Res 2005; 79: 535-44
49. Lopez-Hidalgo M, Salgado-Puga K, Alvarado-Martinez R, Medina AC, Prado-Alcala RA, Garcia-Colunga J. Nicotine uses neuron-glia communication to enhance hippocampal synaptic transmission and long-term memory. PLoS One 2012; 7: e49998
50. Lee E, Park HR, Ji ST, Lee Y, Lee J. Baicalein attenuates astroglial activation in the 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridineinduced Parkinson's disease model by downregulating the activations of nuclear factor-kappaB, ERK, and JNK. J Neurosci Res 2014; 92: 130-9
51. Safi R, Gardaneh M, Panahi Y, Maghsoudi N, Zaefizadeh M, Gharib E. Optimized quantities of GDNF overexpressed by engineered astrocytes are critical for protection of neuroblastoma cells against 6-OHDA toxicity. J Mol Neurosci 2012; 46: 654-65
52. Li XZ, Bai LM, Yang YP, et al. Effects of IL-6 secreted from astrocytes on the survival of dopaminergic neurons in lipopolysaccharide- induced inflammation. Neurosci Res 2009; 65: 252-8
53. Saijo K, Winner B, Carson CT, et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation- induced death. Cell 2009; 137: 47-59
54. More SV, Kumar H, Kim IS, Song SY, Choi DK. Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease. Mediat Inflamm 2013; 2013: 952375
55. Sanchez-Guajardo V, Barnum CJ, Tansey MG, Romero-Ramos M. Neuroimmunological processes in Parkinson's disease and their relation to alpha-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro 2013; 5: 113-39
56. Tufekci KU, Meuwissen R, Genc S, Genc K. Inflammation in Parkinson's disease. Adv Protein Chem Struct Biol 2012; 88: 69-132
57. Nagatsu T, Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des 2005; 11: 999-1016
58. Ono K, Toyono T, Inenaga K. Nicotinic receptor subtypes in rat subfornical organ neurons and glial cells. Neuroscience 2008; 154: 994-1001
59. Xiu J, Nordberg A, Zhang JT, Guan ZZ. Expression of nicotinic receptors on primary cultures of rat astrocytes and up-regulation of the alpha7, alpha4 and beta2 subunits in response to nanomolar concentrations of the beta-amyloid peptide(1-42). Neurochem Int 2005; 47: 281-90
60. Fellin T. Communication between neurons and astrocytes: relevance to the modulation of synaptic and network activity. J Neurochem 2009; 108: 533-44
61. Agulhon C, Fiacco TA, McCarthy KD. Hippocampal short- and long-term plasticity are not modulated by astrocyte Ca2+ signaling. Science 2010; 327: 1250-4
62. Paixao S, Klein R. Neuron-astrocyte communication and synaptic plasticity. Curr Opin Neurobiol 2010; 20: 466-73
63. Allen NJ. Astrocyte regulation of synaptic behavior. Annu Rev Cell Dev Biol 2014; 30: 439-63
64. Haydon PG, Nedergaard M. How do astrocytes participate in neural plasticity? Cold Spring Harb Perspect Biol 2014; 7: a020438
65. Danbolt NC. Glutamate uptake. Prog Neurobiol 2001; 65: 1-105
66. Kullmann DM, Asztely F. Extrasynaptic glutamate spillover in the hippocampus: evidence and implications. Trends Neurosci 1998; 21: 8-14
67. Skucas VA, Mathews IB, Yang J, et al. Impairment of select forms of spatial memory and neurotrophin-dependent synaptic plasticity by deletion of glial aquaporin-4. J Neurosci 2011; 31: 6392-7
68. Magistretti PJ. Neuron-glia metabolic coupling and plasticity. J Exp Biol 2006; 209: 2304-11
69. Bernardinelli Y, Salmon C, Jones EV, Farmer WT, Stellwagen D, Murai KK. Astrocytes display complex and localized calcium responses to single-neuron stimulation in the hippocampus. J Neurosci 2011; 31: 8905-19
70. Henneberger C, Rusakov DA. Synaptic plasticity and Ca2+ signalling in astrocytes. Neuron Glia Biol 2010; 6: 141-6
71. Bernardinelli Y, Muller D, Nikonenko I. Astrocyte-synapse structural plasticity. Neural Plast 2014; 2014: 232105
72. Chen J, Tan Z, Zeng L, et al. Heterosynaptic long-term depression mediated by ATP released from astrocytes. Glia 2013; 61: 178-91
73. Etherington LA, Patterson GE, Meechan L, et al. Astrocytic adenosine kinase regulates basal synaptic adenosine levels and seizure activity but not activity-dependent adenosine release in the hippocampus. Neuropharmacology 2009; 56: 429-37
74. Olmos G, Llado J. Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Mediat Inflamm 2014; 2014: 861231
75. Dhandapani KM, Wade FM, Mahesh VB, Brann DW. Astrocytederived transforming growth factor-{beta} mediates the neuroprotective effects of 17{beta}-estradiol: involvement of nonclassical genomic signaling pathways. Endocrinology 2005; 146: 2749-59
76. Jones EV, Bernardinelli Y, Tse YC, Chierzi S, Wong TP, Murai KK. Astrocytes control glutamate receptor levels at developing synapses through SPARC-beta-integrin interactions. J Neurosci 2011; 31: 4154-65
77. Panatier A, Theodosis DT, Mothet JP, et al. Glia-derived D-serine controls NMDA receptor activity and synaptic memory. Cell 2006; 125: 775-84
78. Henneberger C, Papouin T, Oliet SH, Rusakov DA. Long-term potentiation depends on release of D-serine from astrocytes. Nature 2010; 463: 232-6
79. Gordon GR, Iremonger KJ, Kantevari S, Ellis-Davies GC, MacVicar BA, Bains JS. Astrocyte-mediated distributed plasticity at hypothalamic glutamate synapses. Neuron 2009; 64: 391-403
80. Huang YH, Sinha SR, Tanaka K, Rothstein JD, Bergles DE. Astrocyte glutamate transporters regulate metabotropic glutamate receptor- mediated excitation of hippocampal interneurons. J Neurosci 2004; 24: 4551-9
81. Lee CJ, Mannaioni G, Yuan H, Woo DH, Gingrich MB, Traynelis SF. Astrocytic control of synaptic NMDA receptors. J Physiol 2007; 581: 1057-81
82. Pascual O, Casper KB, Kubera C, et al. Astrocytic purinergic signaling coordinates synaptic networks. Science 2005; 310: 113-6
83. Perea G, Araque A. Astrocytes potentiate transmitter release at single hippocampal synapses. Science 2007; 317: 1083-6
84. Andersson MS, Hanse E. Astrocyte-mediated short-term synaptic depression in the rat hippocampal CA1 area: two modes of decreasing release probability. BMC Neurosci 2011; 12: 87
85. Dervan AG, Meshul CK, Beales M, et al. Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease. Exp Neurol 2004; 190: 145-56
86. Villalba RM, Smith Y. Neuroglial plasticity at striatal glutamatergic synapses in Parkinson's disease. Front Syst Neurosci 2011; 5: 68
87. Grybko M, Sharma G, Vijayaraghavan S. Functional distribution of nicotinic receptors in CA3 region of the hippocampus. J Mol Neurosci 2010; 40: 114-20